{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:46:08Z","timestamp":1793324768890,"version":"4.5.0"},"reference-count":42,"publisher":"American Society of Hematology","issue":"9","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) leads to vaso-occlusive episodes (VOEs) releasing cell-free hemoglobin (Hb) and heme that drive oxidative stress, inflammation, and microvascular dysfunction. Current treatments for VOEs remain limited with no targeted therapies addressing these hemolytic byproducts. This study investigated the potential of an apohemoglobin-haptoglobin (ApoHb-Hp) complex (protein scavenger of both Hb and heme) vs Hp (scavenger of only Hb), in transgenic SCD mice exposed to hypoxia-reoxygenation. Briefly, HbSS-Townes mice instrumented with a dorsal skinfold window chamber received ApoHb-Hp (150 mg\/kg), Hp alone (150 mg\/kg), or an equal volume of saline vehicle, and groups were compared with HbAA controls. At the same dose, ApoHb-Hp had reduced Hb-binding capacity compared with Hp alone, but it possessed heme-binding capacity from the associated ApoHb moiety. Despite the reduced Hb-binding capacity, ApoHb-Hp produced significantly greater protective effects than Hp alone. During hypoxia, ApoHb-Hp preserved &amp;gt;90% of baseline arteriolar and venular flow, whereas untreated and Hp-treated mice exhibited &amp;gt;50% reductions. Functional capillary density at 72 hours post-hypoxia declined by 80% in untreated mice and 44% in Hp-treated mice, but only 27% in ApoHb-Hp\u2013treated mice. Pulmonary inflammation was significantly lower in ApoHb-Hp\u2013treated mice compared with Hp-treated mice, with reduced numbers of macrophages (15 \u00b1 2 vs 18 \u00b1 3), neutrophils (5 \u00b1 1 vs 7 \u00b1 1), and lymphocytes (18 \u00b1 4 vs 20 \u00b1 3). The increased effectiveness of ApoHb-Hp is due to its unique dual-scavenging mechanism. This addresses both Hb and heme toxicity, which each contribute to the pathophysiology of SCD. These findings indicate that the ApoHb-Hp complex is a promising therapeutic option for SCD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2025018529","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T21:51:01Z","timestamp":1769032261000},"page":"3154-3164","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":3,"title":["Apohemoglobin-haptoglobin complex is a therapeutic against vaso-occlusive crisis: scavenging of hemoglobin and heme"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4832-3661","authenticated-orcid":false,"given":"Carlos J.","family":"Munoz","sequence":"first","affiliation":[{"name":"1Department of Bioengineering, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4035-0027","authenticated-orcid":false,"given":"Ivan S.","family":"Pires","sequence":"additional","affiliation":[{"name":"2William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0101-4628","authenticated-orcid":false,"given":"Daniela","family":"Lucas","sequence":"additional","affiliation":[{"name":"1Department of Bioengineering, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Muller","sequence":"additional","affiliation":[{"name":"1Department of Bioengineering, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6075-3623","authenticated-orcid":false,"given":"Jacinda","family":"Martinez","sequence":"additional","affiliation":[{"name":"1Department of Bioengineering, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srila","family":"Gopal","sequence":"additional","affiliation":[{"name":"3Department of Medicine, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre F.","family":"Palmer","sequence":"additional","affiliation":[{"name":"2William G. Lowrie Department of Chemical and Biomolecular Engineering, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8794-2839","authenticated-orcid":false,"given":"Pedro","family":"Cabrales","sequence":"additional","affiliation":[{"name":"1Department of Bioengineering, University of California San Diego, La Jolla, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,5,1]]},"reference":[{"key":"2026051211564650900_bib1","volume-title":"Guidelines for Standard of Care of Acute Painful Episodes in Patients with Sickle Cell Disease","author":"Ballas","year":"1996","edition":"1st ed"},{"issue":"3","key":"2026051211564650900_bib2","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.pcl.2018.01.005","article-title":"Treatment options for sickle cell disease","volume":"65","author":"Meier","year":"2018","journal-title":"Pediatr Clin North Am"},{"issue":"2","key":"2026051211564650900_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in sickle cell disease: drug review","volume":"30","author":"Agrawal","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"issue":"2","key":"2026051211564650900_bib4","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/(SICI)1096-8652(199806)58:2<117::AID-AJH5>3.0.CO;2-V","article-title":"Oral L-glutamine therapy for sickle cell anemia: I. Subjective clinical improvement and favorable change in red cell NAD redox potential","volume":"58","author":"Niihara","year":"1998","journal-title":"Am J Hematol"},{"issue":"17","key":"2026051211564650900_bib5","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2018-08-868893","article-title":"A phase 1\/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease","volume":"133","author":"Howard","year":"2019","journal-title":"Blood"},{"issue":"5","key":"2026051211564650900_bib6","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease","volume":"376","author":"Ataga","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051211564650900_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.3324\/haematol.2019.229989","article-title":"Innate immune cells, major protagonists of sickle cell disease pathophysiology","volume":"105","author":"Allali","year":"2020","journal-title":"Haematologica"},{"issue":"7","key":"2026051211564650900_bib8","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1182\/blood.V92.7.2551","article-title":"Plasma endothelin-1, cytokine, and prostaglandin E2 levels in sickle cell disease and acute vaso-occlusive sickle crisis","volume":"92","author":"Graido-Gonzalez","year":"1998","journal-title":"Blood"},{"issue":"5","key":"2026051211564650900_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJM198408023110504","article-title":"Effects of oxygen inhalation on endogenous erythropoietin kinetics, erythropoiesis, and properties of blood cells in sickle-cell anemia","volume":"311","author":"Embury","year":"1984","journal-title":"N Engl J Med"},{"issue":"2","key":"2026051211564650900_bib10","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/ATVBAHA.120.315081","article-title":"Xanthine oxidase drives hemolysis and vascular malfunction in sickle cell disease","volume":"41","author":"Schmidt","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"38","key":"2026051211564650900_bib11","doi-asserted-by":"crossref","first-page":"33567","DOI":"10.1074\/jbc.M111.228650","article-title":"Mechanisms of slower nitric oxide uptake by red blood cells and other hemoglobin-containing vesicles","volume":"286","author":"Azarov","year":"2011","journal-title":"J Biol Chem"},{"issue":"2","key":"2026051211564650900_bib12","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ccc.2019.12.011","article-title":"A review on microvascular hemodynamics: the control of blood flow distribution and tissue oxygenation","volume":"36","author":"Munoz","year":"2020","journal-title":"Crit Care Clin"},{"issue":"2","key":"2026051211564650900_bib13","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1089\/ars.2009.2822","article-title":"Heme degradation and vascular injury","volume":"12","author":"Belcher","year":"2010","journal-title":"Antioxid Redox Signal"},{"issue":"12","key":"2026051211564650900_bib14","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1089\/ars.2007.1787","article-title":"Heme oxygenase, and ferritin: how the vascular endothelium survives (and dies) in an iron-rich environment","volume":"9","author":"Balla","year":"2007","journal-title":"Antioxid Redox Signal"},{"issue":"10","key":"2026051211564650900_bib15","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1089\/ars.2008.2043","article-title":"Heme oxygenase-1 and the vascular bed: from molecular mechanisms to therapeutic opportunities","volume":"10","author":"Loboda","year":"2008","journal-title":"Antioxid Redox Signal"},{"issue":"26","key":"2026051211564650900_bib16","doi-asserted-by":"crossref","first-page":"15215","DOI":"10.1073\/pnas.221292098","article-title":"Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease","volume":"98","author":"Aslan","year":"2001","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"2026051211564650900_bib17","doi-asserted-by":"crossref","first-page":"630","DOI":"10.3390\/jcm11030630","article-title":"Plasma-derived hemopexin as a candidate therapeutic agent for acute vaso-occlusion in sickle cell disease: preclinical evidence","volume":"11","author":"Gentinetta","year":"2022","journal-title":"J Clin Med"},{"issue":"4","key":"2026051211564650900_bib18","doi-asserted-by":"crossref","first-page":"e0196455","DOI":"10.1371\/journal.pone.0196455","article-title":"Haptoglobin and hemopexin inhibit vaso-occlusion and inflammation in murine sickle cell disease: role of heme oxygenase-1 induction","volume":"13","author":"Belcher","year":"2018","journal-title":"PLoS One"},{"issue":"3","key":"2026051211564650900_bib19","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1182\/blood-2013-04-495887","article-title":"Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease","volume":"123","author":"Belcher","year":"2014","journal-title":"Blood"},{"issue":"5","key":"2026051211564650900_bib20","doi-asserted-by":"crossref","first-page":"H1296","DOI":"10.1152\/ajpheart.00136.2020","article-title":"Apohemoglobin-haptoglobin complex attenuates the pathobiology of circulating acellular hemoglobin and heme","volume":"318","author":"Munoz","year":"2020","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"2","key":"2026051211564650900_bib21","doi-asserted-by":"crossref","first-page":"e0263424","DOI":"10.1371\/journal.pone.0263424","article-title":"Reduced blood pressure in sickle cell disease is associated with decreased angiotensin converting enzyme (ACE) activity and is not modulated by ACE inhibition","volume":"17","author":"Brito","year":"2022","journal-title":"PLOS ONE"},{"issue":"35","key":"2026051211564650900_bib22","first-page":"E5182","article-title":"Sickle cell anemia mice develop a unique cardiomyopathy with restrictive physiology","volume":"113","author":"Bakeer Nihal","year":"2016","journal-title":"Proc Natl Acad Sci"},{"issue":"5339","key":"2026051211564650900_bib23","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.278.5339.876","article-title":"Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease","volume":"278","author":"P\u00e1szty Chris","year":"1997","journal-title":"Science"},{"issue":"4","key":"2026051211564650900_bib24","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1182\/blood-2005-07-2839","article-title":"Pathology of Berkeley sickle cell mice: similarities and differences with human sickle cell disease","volume":"107","author":"Manci","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2026051211564650900_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/s00423-010-0727-x","article-title":"Intestinal ischemia\/reperfusion: microcirculatory pathology and functional consequences","volume":"396","author":"Vollmar","year":"2011","journal-title":"Langenbecks Arch Surg"},{"issue":"1","key":"2026051211564650900_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/00024382-199707000-00002","article-title":"Capillary dysfunction in striated muscle ischemia\/reperfusion: on the mechanisms of capillary \"no-reflow\"","volume":"8","author":"Menger","year":"1997","journal-title":"Shock (Augusta, Ga.)"},{"key":"2026051211564650900_bib27","doi-asserted-by":"crossref","first-page":"1379967","DOI":"10.3389\/fimmu.2024.1379967","article-title":"The clinical relevance of heme detoxification by the macrophage heme oxygenase system","volume":"15","author":"Yeudall","year":"2024","journal-title":"Front Immunol"},{"issue":"5","key":"2026051211564650900_bib28","doi-asserted-by":"crossref","first-page":"C1036","DOI":"10.1152\/ajpcell.00164.2003","article-title":"Methemoglobin is a potent activator of endothelial cells by stimulating IL-6 and IL-8 production and E-selectin membrane expression","volume":"285","author":"Liu","year":"2003","journal-title":"Am J Physiol Cell Physiol"},{"issue":"11","key":"2026051211564650900_bib29","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1080\/15216540500380871","article-title":"Hemoglobin and heme scavenging","volume":"57","author":"Ascenzi","year":"2005","journal-title":"IUBMB life"},{"key":"2026051211564650900_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev-bioeng-081622-031203","article-title":"Engineering therapeutics to detoxify hemoglobin, heme, and iron","volume":"25","author":"Pires","year":"2023","journal-title":"Annu Rev Biomed Eng"},{"issue":"21","key":"2026051211564650900_bib31","doi-asserted-by":"crossref","first-page":"4284","DOI":"10.1182\/blood-2009-10-245001","article-title":"Transfusion of red blood cells after prolonged storage produces harmful effects that are mediated by iron and inflammation","volume":"115","author":"Hod","year":"2010","journal-title":"Blood"},{"issue":"13","key":"2026051211564650900_bib32","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1182\/blood.2020004964","article-title":"Macrophage metabolic adaptation to heme detoxification involves CO-dependent activation of the pentose phosphate pathway","volume":"136","author":"Bories","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2026051211564650900_bib33","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2015-08-663245","article-title":"Hemopexin therapy reverts heme-induced proinflammatory phenotypic switching of macrophages in a mouse model of sickle cell disease","volume":"127","author":"Vinchi","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2026051211564650900_bib34","doi-asserted-by":"crossref","first-page":"H271","DOI":"10.1152\/ajpheart.00078.2012","article-title":"Increased hemoglobin O2 affinity protects during acute hypoxia","volume":"303","author":"Yalcin","year":"2012","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"2026051211564650900_bib35","doi-asserted-by":"crossref","first-page":"H49","DOI":"10.1152\/ajpheart.00665.2010","article-title":"Reversal of hemoglobin-induced vasoconstriction with sustained release of nitric oxide","volume":"300","author":"Cabrales","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2026051211564650900_bib36","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.3389\/fimmu.2020.01964","article-title":"TLR4 signaling by heme and the role of heme-binding blood proteins","volume":"11","author":"Janciauskiene","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2026051211564650900_bib37","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.resuscitation.2007.03.010","article-title":"Transfusion restores blood viscosity and reinstates microvascular conditions from hemorrhagic shock independent of oxygen carrying capacity","volume":"75","author":"Cabrales","year":"2007","journal-title":"Resuscitation"},{"issue":"6","key":"2026051211564650900_bib38","first-page":"549","article-title":"Increase plasma viscosity sustains microcirculation after resuscitation from hemorrhagic shock and continuous bleeding","volume":"23","author":"Cabrales","year":"2005","journal-title":"Shock"},{"key":"2026051211564650900_bib39","doi-asserted-by":"crossref","first-page":"585638","DOI":"10.3389\/fmed.2020.585638","article-title":"Resuscitation after hemorrhagic shock in the microcirculation: targeting optimal oxygen delivery in the design of artificial blood substitutes","volume":"7","author":"Munoz","year":"2020","journal-title":"Front Med"},{"issue":"3","key":"2026051211564650900_bib40","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1172\/JCI89741","article-title":"Intravascular hemolysis and the pathophysiology of sickle cell disease","volume":"127","author":"Kato","year":"2017","journal-title":"J Clin Invest"},{"issue":"6","key":"2026051211564650900_bib41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1365-2141.2012.09143.x","article-title":"Sickle-cell disease and the heart: review of the current literature","volume":"157","author":"Voskaridou","year":"2012","journal-title":"Br J Haematol"},{"issue":"22","key":"2026051211564650900_bib42","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1056\/NEJM199711273372203","article-title":"Circulating activated endothelial cells in sickle cell anemia","volume":"337","author":"Solovey","year":"1997","journal-title":"N Engl J Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3154\/2516771\/blooda_adv-2025-018529-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/9\/3154\/2516771\/blooda_adv-2025-018529-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T15:56:59Z","timestamp":1778601419000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/9\/3154\/566166\/Apohemoglobin-haptoglobin-complex-is-a-therapeutic"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,1]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,5,12]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025018529","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,12]]},"published":{"date-parts":[[2026,5,1]]}}}